Despite a drop in the number of new cases in several countries,
the global Covid-19 caseload is fast approaching the 176-million mark.
The total caseload reached 175,878,310 while the death toll climbed to 3,799,883 as of Monday morning, according to John Hopkins University (JHU).
So far, 2,342, 590,769 doses of vaccine have been administered across the globe.
The US, which has been the world worst hit country in number of cases and deaths, has logged 33,461,575 cases with 599,768 deaths.
Brazil on Sunday registered 1,129 more deaths, bringing the nationwide tally to 487,401, the health ministry said.
A total of 37,948 new infections were detected, raising the caseload to 17,412,766, the ministry said.
Brazil has the world’s second highest Covid-19 death toll, after the United States, and the third largest caseload, following the United States and India.
Besides, India’s Covid-19 tally rose to 29,439,989 on Sunday, with as many as 80,834 new cases recorded in the past 24 hours, said the health ministry.
Besides, 3,303 Covid-19 patients died in 24 hours until Saturday morning taking the death toll to 370,384.
Situation in Bangladesh
Amid the growing concern over the rapidly increasing cases and the higher transmissibility of Delta variant, Bangladesh registered 2,436 new Covid cases in 24 hours till Sunday morning.
The deadly virus also claimed 47 more lives during the period, pushing up the fatalities to 13,118, said a handout released by the Directorate General of Health Services (DGHS).
The caseload reached 8,26,922 with the logging of the new cases.
Vaccination drive
Bangladesh, the prime recipient of Oxford-AstraZeneca vaccines, has suspended the registration for Covid-19 jabs due to vaccine shortage amid a delay in the arrival of shipments from India.
Some 42,05,167 people got the second dose of this vaccine while the number is 58,20,015 for the first one.
Besides, the total number of people receiving their first jab of Chinese Sinopharm vaccine is 2,162.
So far, four vaccines – Oxford-AstraZeneca (Covishield), Sputnik-V, Sinopharm, and Pfizer-BioNTech – have got the approval for emergency use in Bangladesh.
